Erfan Amini1,2, Tracy Campanelli Palmer1, Jie Cai1, Gary Lieskovsky1, Siamak Daneshmand1, Hooman Djaladat3. 1. The Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 2. Department of Urology, Uro-oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran. 3. The Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. djaladat@med.usc.edu.
Abstract
PURPOSE: Few studies have evaluated prostate cancer oncologic outcomes in different ethnic groups following radical prostatectomy for clinically organ-confined disease. Existing studies lack long-term outcome data. We conducted this study to assess the impact of racial differences on risk profile and oncologic outcomes in a large cohort of patients with prostate cancer who underwent radical prostatectomy. METHODS: Using our institutional review board-approved prostate cancer database, we retrospectively reviewed the records of 3437 patients who underwent radical prostatectomy with curative intent in our institution between 1987 and 2009. Based on ethnicity, patients were divided into Asian Americans (n = 133), African Americans (n = 155) and Caucasians (n = 3149). Baseline characteristics and oncologic outcomes including biochemical recurrence free, clinical recurrence free and overall survival were compared between the study groups. RESULTS: A total of 3437 patients with a mean age of 63 ± 9.8 years and median follow-up period of 8.7 (range 0.1-24.1) years were included in the analysis. Pathologic stage and the frequency of poorly differentiated cancer were higher in Asian Americans; however, margin status did not differ significantly. Moreover, oncologic outcomes were comparable between different ethnic groups. In multivariate analysis, both pathologic stage and grade were independent predictors of oncologic outcomes, but race was not. CONCLUSIONS: In this large, ethnically diverse long-term follow-up study, we noted that Asian Americans compared to African Americans and Caucasians are more likely to have high risk prostate cancer; however, race was not an independent predictor of oncologic outcome following radical prostatectomy with curative intent.
PURPOSE: Few studies have evaluated prostate cancer oncologic outcomes in different ethnic groups following radical prostatectomy for clinically organ-confined disease. Existing studies lack long-term outcome data. We conducted this study to assess the impact of racial differences on risk profile and oncologic outcomes in a large cohort of patients with prostate cancer who underwent radical prostatectomy. METHODS: Using our institutional review board-approved prostate cancer database, we retrospectively reviewed the records of 3437 patients who underwent radical prostatectomy with curative intent in our institution between 1987 and 2009. Based on ethnicity, patients were divided into Asian Americans (n = 133), African Americans (n = 155) and Caucasians (n = 3149). Baseline characteristics and oncologic outcomes including biochemical recurrence free, clinical recurrence free and overall survival were compared between the study groups. RESULTS: A total of 3437 patients with a mean age of 63 ± 9.8 years and median follow-up period of 8.7 (range 0.1-24.1) years were included in the analysis. Pathologic stage and the frequency of poorly differentiated cancer were higher in Asian Americans; however, margin status did not differ significantly. Moreover, oncologic outcomes were comparable between different ethnic groups. In multivariate analysis, both pathologic stage and grade were independent predictors of oncologic outcomes, but race was not. CONCLUSIONS: In this large, ethnically diverse long-term follow-up study, we noted that Asian Americans compared to African Americans and Caucasians are more likely to have high risk prostate cancer; however, race was not an independent predictor of oncologic outcome following radical prostatectomy with curative intent.
Authors: M J Resnick; D J Canter; T J Guzzo; B M Brucker; M Bergey; S S Sonnad; A J Wein; S B Malkowicz Journal: Urology Date: 2008-12-18 Impact factor: 2.649
Authors: Jeffrey J Tosoian; Fawaz Almutairi; Carlos L Morais; Stephanie Glavaris; Jessica Hicks; Debasish Sundi; Elizabeth Humphreys; Misop Han; Angelo M De Marzo; Ashley E Ross; Scott A Tomlins; Edward M Schaeffer; Bruce J Trock; Tamara L Lotan Journal: Eur Urol Date: 2016-07-28 Impact factor: 20.096
Authors: Scott P Kelly; Philip S Rosenberg; William F Anderson; Gabriella Andreotti; Naji Younes; Sean D Cleary; Michael B Cook Journal: Eur Urol Date: 2016-07-27 Impact factor: 20.096
Authors: Debasish Sundi; Ashley E Ross; Elizabeth B Humphreys; Misop Han; Alan W Partin; H Ballentine Carter; Edward M Schaeffer Journal: J Clin Oncol Date: 2013-06-17 Impact factor: 44.544
Authors: Farzana A Faisal; Debasish Sundi; Jeffrey J Tosoian; Voleak Choeurng; Mohammed Alshalalfa; Ashley E Ross; Eric Klein; Robert Den; Adam Dicker; Nicholas Erho; Elai Davicioni; Tamara L Lotan; Edward M Schaeffer Journal: Eur Urol Date: 2015-10-09 Impact factor: 20.096
Authors: Isaac J Powell; Greg Dyson; Susan Land; Julie Ruterbusch; Cathryn H Bock; Steve Lenk; Mehsati Herawi; Richard Everson; Craig N Giroux; Ann G Schwartz; Aliccia Bollig-Fischer Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-20 Impact factor: 4.254
Authors: Valentin H Meissner; Jamila G H Strüh; Martina Kron; Lea A Liesenfeld; Stephanie Kranz; Jürgen E Gschwend; Kathleen Herkommer Journal: World J Urol Date: 2020-03-11 Impact factor: 4.226
Authors: Mike Wenzel; Christoph Würnschimmel; Luigi Nocera; Claudia Colla Ruvolo; Benedikt Hoeh; Zhe Tian; Shahrokh F Shariat; Fred Saad; Alberto Briganti; Markus Graefen; Felix Preisser; Andreas Becker; Philipp Mandel; Felix K H Chun; Pierre I Karakiewicz Journal: Front Oncol Date: 2022-08-19 Impact factor: 5.738